Israel Englander Ocugen, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.5 - $1.83 $757,396 - $2.77 Million	1,514,792 Added 368.6%	1,925,755 $3.16 Million
Q4 2023 Feb 14, 2024	SELL	$0.36 - $0.57 $938,006 - $1.49 Million	-2,605,574 Reduced 86.38%	410,963 $234,000
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $786,984 - $1.54 Million	1,748,855 Added 137.96%	3,016,537 $1.63 Million
Q1 2023 May 15, 2023	BUY	$0.82 - $1.33 $1.04 Million - $1.69 Million	1,267,682 New	1,267,682 $1.08 Million
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $165,935 - $293,942	94,820 Added 61.15%	249,878 $445,000

108

66.5M

516K

272K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $214M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.